Isolation of circulating tumor cells using a microvortex-generating herringbone-chip
Open Access
- 7 October 2010
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 107 (43), 18392-18397
- https://doi.org/10.1073/pnas.1012539107
Abstract
Rare circulating tumor cells (CTCs) present in the bloodstream of patients with cancer provide a potentially accessible source for detection, characterization, and monitoring of nonhematological cancers. We previously demonstrated the effectiveness of a microfluidic device, the CTC-Chip, in capturing these epithelial cell adhesion molecule (EpCAM)-expressing cells using antibody-coated microposts. Here, we describe a high-throughput microfluidic mixing device, the herringbone-chip, or “HB-Chip,” which provides an enhanced platform for CTC isolation. The HB-Chip design applies passive mixing of blood cells through the generation of microvortices to significantly increase the number of interactions between target CTCs and the antibody-coated chip surface. Efficient cell capture was validated using defined numbers of cancer cells spiked into control blood, and clinical utility was demonstrated in specimens from patients with prostate cancer. CTCs were detected in 14 of 15 (93%) patients with metastatic disease (median = 63 CTCs/mL, mean = 386 ± 238 CTCs/mL), and the tumor-specific TMPRSS2-ERG translocation was readily identified following RNA isolation and RT-PCR analysis. The use of transparent materials allowed for imaging of the captured CTCs using standard clinical histopathological stains, in addition to immunofluorescence-conjugated antibodies. In a subset of patient samples, the low shear design of the HB-Chip revealed microclusters of CTCs, previously unappreciated tumor cell aggregates that may contribute to the hematogenous dissemination of cancer.Keywords
This publication has 31 references indexed in Scilit:
- Isolation and Characterization of Circulating Tumor Cells from Patients with Localized and Metastatic Prostate CancerScience Translational Medicine, 2010
- Highly efficient capture and enumeration of low abundance prostate cancer cells using prostate‐specific membrane antigen aptamers immobilized to a polymeric microfluidic deviceElectrophoresis, 2009
- Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial dataThe Lancet Oncology, 2009
- Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper deviceProceedings of the National Academy of Sciences of the United States of America, 2009
- Enrichment of Cancer Cells Using Aptamers Immobilized on a Microfluidic ChannelAnalytical Chemistry, 2008
- Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experienceAnnals of Oncology, 2008
- Detection of Mutations inEGFRin Circulating Lung-Cancer CellsThe New England Journal of Medicine, 2008
- Highly Efficient Circulating Tumor Cell Isolation from Whole Blood and Label-Free Enumeration Using Polymer-Based Microfluidics with an Integrated Conductivity SensorJournal of the American Chemical Society, 2008
- Isolation of rare circulating tumour cells in cancer patients by microchip technologyNature, 2007
- High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activityAnnals of Oncology, 2007